| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | August 22, 2022 |
| Accession Number: | 0001140361-22-029967 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/20/2022 | $58.00 | Buy | BofA Securities |
| 3/1/2022 | $50.00 → $45.00 | Hold | Stifel |
| 2/10/2022 | $120.00 → $85.00 | Overweight | Wells Fargo |
| 1/21/2022 | $115.00 → $105.00 | Outperform | Oppenheimer |
| 12/7/2021 | Outperform | Cowen & Co. | |
| 11/10/2021 | $150.00 → $115.00 | Outperform | Oppenheimer |
| 10/12/2021 | $178.00 → $162.00 | Buy | HC Wainwright & Co. |
| 10/11/2021 | Market Outperform → Market Perform | JMP Securities |
-- Oversubscribed financing brings together leading syndicate of life sciences investors -- -- Proceeds to support clinical development of first-in-class therapies for neurological disorders – BOSTON, Oct. 30, 2024 /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed $115 million Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essent
- venBio promotes Yvonne Yamanaka, Ph.D. to Partner venBio today announced the closing of venBio Global Strategic Fund V ("venBio Fund V"), its fifth life sciences venture capital fund, exceeding its target and closing on approximately $528 million in capital commitments in an oversubscribed fundraise. The firm initiated the fundraise for Fund V in mid-April. Limited partners of Fund V include a broad range of institutional investors comprising sovereign wealth funds, corporate pensions, financial institutions, university endowments, medical institutions, foundations, family offices and funds-of-funds. Under the fund leadership of Managing Partners Richard Gaster, M.D., Ph.D., Corey Goo
NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and
4 - Turning Point Therapeutics, Inc. (0001595893) (Issuer)
4 - Turning Point Therapeutics, Inc. (0001595893) (Issuer)
4 - Turning Point Therapeutics, Inc. (0001595893) (Issuer)
15-12G - Turning Point Therapeutics, Inc. (0001595893) (Filer)
EFFECT - Turning Point Therapeutics, Inc. (0001595893) (Filer)
S-8 POS - Turning Point Therapeutics, Inc. (0001595893) (Filer)
SC 13G - Turning Point Therapeutics, Inc. (0001595893) (Subject)
SC 13G/A - Turning Point Therapeutics, Inc. (0001595893) (Subject)
SC 13G/A - Turning Point Therapeutics, Inc. (0001595893) (Subject)